title: In vitro activity of BAY v 3522, a new cephalosporin for oral administration.
abstract: The activity of BAY v 3522 was tested against over 500 clinical bacterial isolates and compared with the activities of ampicillin, amoxicillin-clavulanate, cefaclor, cefixime, cefuroxime, cephalexin, and/or ciprofloxacin, erythromycin, and metronidazole. BAY v 3522 activity against staphylococci and streptococci equaled or exceeded those of the other agents. BAY v 3522 exhibited no significant advantage over cefaclor, cefuroxime, or cephalexin against gram-negative bacilli.
authors.affiliation: Department of Medicine, New England Deaconess Hospital, Boston, Massachusetts.
authors.forename: T L
authors.initials: TL
authors.lastname: Hodges
authors.forename: G M
authors.initials: GM
authors.lastname: Eliopoulos
authors.forename: K
authors.initials: K
authors.lastname: Klimm
authors.forename: R C
authors.initials: RC
authors.lastname: Moellering
mesh_terms: D000284:Administration, Oral; D001419:Bacteria / Q000187:drug effects; D052160:Benzothiazoles; D002511:Cephalosporins / Q000008:administration & dosage / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D013210:Staphylococcus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects
chemical_list: D052160:Benzothiazoles; D002511:Cephalosporins; C064738:Bay v 3522